1Isaacs C, Robert N J, Bailey FA, et al. Randomized placebo - controlled study of recombinant human interleukin - 11 to pre- vent chemotherapy- induced thrombocytopenia in patients with breast cancer receiving dose - intensive cyclophosphamide and doxorubicin[ J]. J Clin Ontol,1997,15 ( 11 ) :3368 - 3377.
3FREEDM AN J. Random bonor platelet crosmatching[J]. C stud Hematol Blood Transfusion, 1986,5 (2) : 65.
4KAUSHANSKY K,LOK S,HOLLY R D,et al. Pronmotoin of megakaryoeyto progenitor expansion and differentiation by the c-Mpl ligand throm bopoietin[J ]. Nature, 1994,369:568-571.
7Du X,Williams DA. Interleukin-11: review of molecular, cell biology, and clinical use. Blood, 1997, 89: 3897-3908.
8Kaviani MD, Mason LE, Bree AG, et al. Effects of recombinant human interleukin 11 on the activation and morphology of peripheral blood platelets and megakaryocytes in nonhuman primates. Blood,1996,88 (suppl 1):26-29.
9Bruno E,Briddell R, Cooper R, et al. Effects of recombinant interleukin 11 on human megakaryocyte progenitor cells. Exp Hematol, 1991, 19: 378-381.
10Weich NS, Wang A, Fitzgerald M, et al. Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro. Blood, 1997, 90:3893-3902.
7Isaacs C, Robert N J, Bailey FA, et al. Randomized placebo - controlled study of recombinant human interleukin - 11 to pre- vent chemotherapy- induced thrombocytopenia in patients with breast cancer receiving dose - intensive cyclophosphamide and doxorubicin [ J ]. J Clin Oncol, 1997,15 ( 11 ) : 3368 - 3377.
